Home » News: FDA Awards NIPTE a $35-million Grant to Improve Drug Manufacturing
News: FDA Awards NIPTE a $35-million Grant to Improve Drug Manufacturing
In a move that seeks to cut health care costs, create jobs, and improve drug safety, the US Food and Drug Administration (FDA) has awarded a grant worth up to $35 million over the next five years to the National Institute for Pharmaceutical Technology and Education (NIPTE) to improve drug manufacturing standards. The grant comes at a time when the current cost of bringing a drug to market in the US exceeds $1 billion and an increasing number of drugs and drug ingredients are being imported from abroad. Investment in research of drug development and manufacturing will not only improve America’s manufacturing competitiveness and create high-paying jobs at home, but will help to reverse the current outsourcing trends in the pharmaceutical industry in the long term by decreasing the cost of manufacture and by improving quality and safety of our drugs.
“Over the last several years, NIPTE has contributed a great deal of research toward our understanding of quality pharmaceutical manufacturing,” said Helen N. Winkle, Director, FDA Office of Pharmaceutical Sciences. “Progress in this area will mean safer, more efficient, and less costly drug production here in the US, and we are looking forward to NIPTE’s findings.”
NIPTE, Inc. is an academic not-for-profit organization dedicated to fundamental research and education in pharmaceutical product development and manufacturing. NIPTE's goal is to increase science and engineering-based understanding of this area so that novel state-of- the-art technologies can be developed and science-based regulations can be implemented. These technologies will also enable new drug discoveries to be brought to market faster with less variability, higher predictability of performance and at a significantly lower cost.
“Outsourcing of drugs and drug intermediates are increasing at an alarming rate, potentially threatening overall quality of our drugs accompanied by huge job losses in this country,” said NIPTE Executive Director Prabir Basu. “Development and manufacturing costs can be reduced, quality of our drugs can be improved, and outsourcing trends can be reversed by developing science-based standards for drug development and manufacturing.”
The FDA grant will support programs to rectify these drug development and manufacturing problems, by creating ways to reduce time to market, enabling new performance attributes, improving small-batch production, promote continuous manufacturing, saving money or energy, or reducing environmental impact from the manufacturing of products.
"We are thrilled to see the FDA’s commitment to invest in the science of pharmaceutical manufacturing," said Basu. "I sincerely hope that other federal funding agencies will take the lead from the FDA and will take similar steps to fund this critical area of translational and manufacturing research to improve health care in the US.”
NIPTE partners with 10 U.S. universities that are leaders in pharmaceutical science and engineering. The member universities are Duquesne, University, Illinois Institute of Technology, Purdue University, Rutgers University, University of Puerto Rico, University of Connecticut, University of Iowa, University of Kentucky, University of Maryland - Baltimore, and the University of Minnesota. It is the only partnership of universities of its kind. Research conducted by NIPTE faculty is collaborative by design to provide for coordinated publication of the cutting edge research results.
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
Sun Pharma to Pay Pfizer $550 MillionFrom Bloomberg.com
India's biggest drugmaker Sun Pharma experiencing huge decline after settling patent litigation with Pfizer
Catalent Pharma Solutions Expands Manufacturing Facility
Investment of nearly $35 million will create more than 90 manufacturing jobs for innovative medicines
Cancer Drug Still Denied Approval By FDAFrom USA Today
The FDA continues to refuse approval for Aveo Oncology's cancer drug tivozanib citing unclear data
Ten Countries Approve Impotence DrugFrom BusinessWeek.com
The impotence drug Vitatos by Apricus has been approved in 10 European countries
- All news »